Provider of a bespoke cloud-based e-learning platform intended to provide intensive training courses in life science technologies. The company's bespoke cloud-based e-learning platform offers 2-day intensive courses on all essential aspects of latest scientific technologies, enabling emerging and growing non-EU companies accelerate European market penetration for their most high impact products.
In 2022, CamBioScience revenue run rate hit $664K in revenue.
CamBioScience hit $664K in revenue in 2021
CamBioScience launched in 2015 with $0 revenue
CamBioScience Funding History
Why are so many SaaS founders taking money from Founderpath.com instead of VC`s?
CamBioScience raised a of $2.5M
CamBioScience raised a of $535.3K
CamBioScience raised a of $1.5M
CamBioScience has 12 total employees
Total team size
During his time as a Research Fellow at Homerton College University of Cambridge Dr. Chibeza co-founded OBRIZUM Group Ltd then called CamBioScience Limited with two colleagues from the University of Cambridge. Dr. Agley helped grow the company from its origins as an interdisciplinary academic-to-industry consultancy service to a fully scalable international technology business supporting multinational corporations in a variety of industries worldwide. OBRIZUM Group Ltd. is creating deep proprietary data driven technologies to revolutionise enterprise learning and knowledge management. OBRIZUM Group Ltd.s core offering is an Artificial Intelligence powered software platform called OBRIZUM that allows large companies working in any vertical to automatically create personalise and measure digital learning and customer engagement at scale. Dr. Agley was instrumental in developing and installing the company s divisional structure which provides financial resilience improved client experience and numerous routes for highly scalable growth. Since founding the business Chibeza has brought in and managed relations with many of the company s largest clients and successfully sourced and closed deals across all three departments. As CEO Chibeza leads the businesss fundraising efforts and has secured funds from Private Equity Venture Capital and Angel investors. He is also responsible for the successful formation of numerous national and international partnerships. With his previous experience in generating and protecting Intellectual Property Dr. Agley spearheads the company s IP strategy.
Chibeza Chintu Agley holds a first-class BSc Hons and the University Prize for best Research Project from Brunel University. As an undergraduate he was co-founder of a cloud platform for students to share and consume information about University life. Chibeza went on to complete an MSc with Distinction and Colt Prize and then a PhD from King s College London in physiology and adult stem cell biology respectively. For his PhD thesis Chibeza was awarded the Tadien Rideal Prize for outstanding doctoral research in the molecular sciences. After finishing his PhD Chibeza began his postdoctoral work at the Cambridge Stem Cell Institute and was then appointed to the position of Research Fellow at Homerton College Cambridge. Chibeza has authored and co-authored 10 peer-reviewed publications and continues to contribute and advise on technical projects across a range of disciplines from software to neuroscience.